LAMA84-s/Cre cells are derived from the human chronic myeloid leukemia cell line LAMA84-s by stably integration of a constitutive Cre recombinase stably expression construct. The LAMA84-s cell line is sensitive to the tyrosine kinase inhibitor imatinib mesylate, and is paired to the LAMA84-r cell line which is resistant to imatinib. The paired LAMA84-s and LAMA84-r cell lines are useful models of sensitivity and resistance to a tyrosine kinase inhibitor used in the treatment of chronic myeloid leukemia. LAMA84-s/Cre cells stably express a nuclear localized Cre recombinase.